Integrated single-cell and proteomic profiling of pancreatic neoplasia identifies tissue markers that outperform established diagnostic markers in distinguishing cancer from precursor lesions.
- 1Department of Surgery, Indiana University School of Medicine
Abstract
Pancreatic ductal adenocarcinoma (PDAC) arises within an extensively remodeled microenvironment, yet tissue markers that distinguish invasive carcinoma from precursor lesions remain limited. Integrating four single-cell RNA-sequencing atlases comprising 324,662 cells from 26 patients, we identified cancer-associated fibroblast expansion, accumulation of C1QA+ immunoregulatory macrophages, and depletion of a dendritic-cell compartment expressing plasmacytoid markers. Fibroblasts were enriched for extracellular-matrix and PI3K-AKT programs and macrophages for an antigen-presentation program. We then examined the protein-level correlates of these populations in a tissue proteomic reference framework of 356 samples spanning non-diseased pancreas, normal-adjacent tissue, low- and high-grade intraductal papillary mucinous neoplasms (IPMNs), IPMN-associated invasive carcinoma, and PDAC, prioritizing proteins that changed monotonically across the six histopathologic reference groups or marked tumor-enriched cell types. Despite depletion of plasmacytoid dendritic cells, the principal source of type I interferon, the interferon-stimulated protein ISG15, expressed by both fibroblasts and macrophages, increased monotonically toward PDAC. In exploratory cross-validated benchmarking of PDAC versus low- and high-grade IPMN, excluding IPMN-associated invasive carcinoma (145 versus 56 samples), CATB+EPIPL achieved an AUC of 0.98, with a sensitivity of 92% at an achieved specificity of 92%, exceeding protein-abundance models of diagnostic IHC-associated markers (S100P+IMP3+maspin+MSLN, 0.79) and refitted published IPMN-progression combinations ([≤]0.91). Against non-diseased pancreas, candidate and comparator panels performed similarly (AUC 0.99-1.00). These biologically informed tissue protein panels warrant independent validation, including immunohistochemical evaluation of EUS-guided fine-needle biopsy specimens and measurement in blood.
Related
- The PancreaSure Multianalyte Blood Test Performs Well at Distinguishing Early-Stage Pancreatic Ductal Adenocarcinoma from High-Risk Controls: A Retrospective Secondary Analysis
- An Integrative RNA Spliceosomic Landscape of Pancreatic Neuroendocrine Tumors Identifies Clinically Relevant Molecular Subgroups
- Integrated bioinformatic analysis identifies distinct neddylation-associated proteasome genes and immune-related features in laryngeal squamous cell carcinoma
- Integrated Transcriptomic Analysis Identifies ENO3 as a Candidate Lactate Metabolism‐Associated Biomarker in Colorectal Cancer Metastasis
- Long-Term Drug Screening Identifies PARP Inhibitors as Irinotecan Combination Partners in BRCA1/2-Wild-Type Pancreatic Ductal Adenocarcinoma.
BibTeX
@misc{tran2026integrated,
title = {{Integrated single-cell and proteomic profiling of pancreatic neoplasia identifies tissue markers that outperform established diagnostic markers in distinguishing cancer from precursor lesions.}},
author = {T. T. Tran and P. U. Nguyen Hoang and D. T. Pham and J. Fahrmann and L. Bui and N. H. Bui and C. M. Schmidt},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.02.26364030},
url = {https://www.medrxiv.org/content/10.64898/2026.10.02.26364030v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Integrated single-cell and proteomic profiling of pancreatic neoplasia identifies tissue markers that outperform established diagnostic markers in distinguishing cancer from precursor lesions.
AU - T. T. Tran
AU - P. U. Nguyen Hoang
AU - D. T. Pham
AU - J. Fahrmann
AU - L. Bui
AU - N. H. Bui
AU - C. M. Schmidt
PY - 2026
DA - 2026/10/02
PB - medRxiv
DO - 10.64898/2026.10.02.26364030
UR - https://www.medrxiv.org/content/10.64898/2026.10.02.26364030v1
AB - Pancreatic ductal adenocarcinoma (PDAC) arises within an extensively remodeled microenvironment, yet tissue markers that distinguish invasive carcinoma from precursor lesions remain limited. Integrating four single-cell RNA-sequencing atlases comprising 324,662 cells from 26 patients, we identified cancer-associated fibroblast expansion, accumulation of C1QA+ immunoregulatory macrophages, and depletion of a dendritic-cell compartment expressing plasmacytoid markers. Fibroblasts were enriched for extracellular-matrix and PI3K-AKT programs and macrophages for an antigen-presentation program. We then examined the protein-level correlates of these populations in a tissue proteomic reference framework of 356 samples spanning non-diseased pancreas, normal-adjacent tissue, low- and high-grade intraductal papillary mucinous neoplasms (IPMNs), IPMN-associated invasive carcinoma, and PDAC, prioritizing proteins that changed monotonically across the six histopathologic reference groups or marked tumor-enriched cell types. Despite depletion of plasmacytoid dendritic cells, the principal source of type I interferon, the interferon-stimulated protein ISG15, expressed by both fibroblasts and macrophages, increased monotonically toward PDAC. In exploratory cross-validated benchmarking of PDAC versus low- and high-grade IPMN, excluding IPMN-associated invasive carcinoma (145 versus 56 samples), CATB+EPIPL achieved an AUC of 0.98, with a sensitivity of 92% at an achieved specificity of 92%, exceeding protein-abundance models of diagnostic IHC-associated markers (S100P+IMP3+maspin+MSLN, 0.79) and refitted published IPMN-progression combinations ([≤]0.91). Against non-diseased pancreas, candidate and comparator panels performed similarly (AUC 0.99-1.00). These biologically informed tissue protein panels warrant independent validation, including immunohistochemical evaluation of EUS-guided fine-needle biopsy specimens and measurement in blood.
ER -